Strategic News: Liquid Biopsy Market to Hit $7.05B by 2030

The global Liquid Biopsy Market is projected to grow from USD 4.03 billion in 2025 to USD 7.05 billion by 2030, at a CAGR of 11.8%. As healthcare systems shift toward minimally invasive diagnostics and precision oncology, liquid biopsy technologies are emerging as a transformative solution for early cancer detection and real-time disease monitoring.

Liquid Biopsy Market

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350

What is driving this market expansion?

The increasing global incidence of cancer, coupled with growing demand for non-invasive and patient-friendly diagnostic tools, is a major catalyst. Liquid biopsy enables clinicians to detect cancer-related biomarkers through simple body fluid samples — primarily blood — eliminating the need for invasive tissue biopsies.

How is technology enhancing adoption?

Breakthroughs in next-generation sequencing (NGS) and PCR-based technologies have significantly improved the sensitivity and specificity of liquid biopsy assays. These advancements allow for more accurate detection of circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and circulating tumor cells (CTCs), enhancing clinical decision-making and patient outcomes.

From a technology perspective, multi-gene parallel analysis using NGS dominated the market in 2024. Why is this segment leading? NGS enables simultaneous analysis of multiple genetic mutations, providing comprehensive molecular profiling. This high-throughput capability is particularly valuable in oncology, where understanding complex genomic alterations is essential for selecting targeted therapies and monitoring treatment response.

In terms of application, the cancer segment accounted for the largest market share in 2024. What explains this dominance? The growing prevalence of cancers such as lung, breast, and prostate cancer has intensified the need for advanced diagnostic tools. Liquid biopsy plays a critical role in oncology by enabling early detection, monitoring tumor progression in real time, and identifying minimal residual disease — capabilities that traditional biopsies often cannot provide.

Additionally, global cancer awareness initiatives and screening programs are encouraging early diagnosis, further increasing demand for accessible and efficient testing solutions.

Regional Analysis:-

North America held the largest share of the liquid biopsy market in 2024. What gives this region a leading edge? A well-established healthcare infrastructure, availability of advanced diagnostic technologies, and the presence of specialized cancer care centers are key contributors. These factors, combined with a highly skilled medical workforce, support the widespread adoption of liquid biopsy in routine clinical practice.

Key players

Key players operating in the liquid biopsy market include Natera, Inc., QIAGEN, Guardant Health, Illumina, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GRAIL, Inc., Bio-Rad Laboratories, Inc., Exact Sciences Corporation, and Sysmex Corporation. These companies are focusing on technological innovation, strategic collaborations, and expanding their diagnostic portfolios to strengthen their market presence.